Izokibep is under clinical development by Acelyrin and currently in the Phase II and Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Izokibep’s likelihood of approval (LoA) and phase transition for Posterior Uveitis took place on 29 Nov 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Izokibep Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Izokibep overview

Izokibep (ABY-035) is under development for the treatment of posterior uveitis, panuveitis, patients with moderate-to-severe plaque psoriasis, active psoriatic arthritis with inflammatory musculoskeletal disease, hidradenitis suppurativa. It is administered through subcutaneous route. ABY-035 is a IL-17A blocking molecule. It is developed based on affibody technology. Affibody molecules are antibody mimetics with superior characteristics surpassing monoclonal antibodies and antibody fragments. It was also under development for Takayasu arteritis.

It was also under development for the treatment of ankylosing spondylitis(AS).

Acelyrin overview

Acelyrin is a biopharma company. It focuses on identifying and developing therapeutics for immunology and other unmet medical needs. The company seeks to collaborate with partners, pharmaceutical companies, early-stage start-ups and academicians in identifying and developing products. It is also involved in the development of Los Angeles Biotech Hub. Acelyrin is funded by Westlake Village BioPartners. The company operates with an additional office in San Francisco Bay area, the US. Acelyrin is headquartered in Woodland Hills, California, the US.

Quick View Izokibep LOA Data

Report Segments
  • Innovator
Drug Name
  • Izokibep
Administration Pathway
  • Subcutaneous
Therapeutic Areas
  • Cardiovascular
  • Dermatology
  • Immunology
  • Musculoskeletal Disorders
  • Ophthalmology
Key Developers
  • Sponsor Company: Acelyrin
  • Originator: Affibody
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.